Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics and tolerability of Delafloxacin in subjects with varying degrees of renal function

Trial Profile

Pharmacokinetics and tolerability of Delafloxacin in subjects with varying degrees of renal function

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Delafloxacin (Primary) ; Delafloxacin (Primary)
  • Indications Community-acquired pneumonia; Skin and soft tissue infections; Urinary tract infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 26 Mar 2018 Results (n=44) assessing pharmacokinetics and tolerability of Delafloxacin in subjects with varying degrees of renal function, were published in the Journal of Clinical Pharmacology.
    • 14 Mar 2018 Results assessing pharmacokinetics between healthy subjects and subjects with end-stage renal disease (n=19) published in the Journal of Clinical Pharmacology
    • 02 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top